Bjelland I, Dahl AA, Haug TT, Neckelmann D The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. Review.
Engström A, Söderberg S The experiences of partners of critically ill persons in an intensive care unit. Intensive Crit Care Nurs. 2004 Oct;20(5):299-308; quiz 309-10.
Fumis RR, Ranzani OT, Martins PS, Schettino G Emotional disorders in pairs of patients and their family members during and after ICU stay. PLoS One. 2015 Jan 23;10(1):e0115332. doi: 10.1371/journal.pone.0115332. eCollection 2015.
Hanson LC, Danis M, Garrett J What is wrong with end-of-life care? Opinions of bereaved family members. J Am Geriatr Soc. 1997 Nov;45(11):1339-44.
McAdam JL, Arai S, Puntillo KA Unrecognized contributions of families in the intensive care unit. Intensive Care Med. 2008 Jun;34(6):1097-101. doi: 10.1007/s00134-008-1066-z. Epub 2008 Mar 28.
Seferian EG, Afessa B Adult intensive care unit use at the end of life: a population-based study. Mayo Clin Proc. 2006 Jul;81(7):896-901.
Silveira MJ, Kim SY, Langa KM Advance directives and outcomes of surrogate decision making before death. N Engl J Med. 2010 Apr 1;362(13):1211-8. doi: 10.1056/NEJMsa0907901.
Villa G, De Gaudio AR, Falsini S, Lanini I, Curtis JR Development of END-of-Life ScorING-System to identify critically ill patients after initial critical care who are highly likely to die: a pilot study. Minerva Anestesiol. 2015 Dec;81(12):1318-28. Epub 2015 Jan 23.
White DB Strategies to Support Surrogate Decision Makers of Patients With Chronic Critical Illness: The Search Continues. JAMA. 2016 Jul 5;316(1):35-7. doi: 10.1001/jama.2016.8691.
PROSPECTIVE EVALUATION OF FAMILY CARE RITUALS IN THE ICU AND VALIDATION OF THE END-of-Life ScorING-System (ENDING-S), a Multicenter, Multinational Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.